Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

NCT04000529 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

122

Enrollment

INDUSTRY

Sponsor class

Stopped Business reasons

Conditions

Non-small Cell Lung Carcinoma
Head and Neck Squamous Cell Carcinoma
Esophageal SCC
Gastrointestinal Stromal Tumors
Colorectal Cancer

Interventions

DRUG: TNO155
DRUG: Spartalizumab
DRUG: Ribociclib

Sponsor

Novartis Pharmaceuticals